Flagstar Bank NA vs Zoetis Inc — how do they compare? Flagstar Bank NA trades at $11.42 (market cap $4.71B), while Zoetis Inc trades at $74.45 (market cap $30.20B). The key difference: Zoetis Inc is far larger — about 6.4× Flagstar Bank NA's market cap, and Zoetis Inc pays the higher dividend (2.9%). Which is the better fit depends on your goals — on Pluang, investors hold Flagstar Bank NA for 22 Days and Zoetis Inc for 70 Days on average.
| FLG | ZTS | |
|---|---|---|
Market Cap | $4.71B | $30.20B |
Volume | 7,410,589 | 6,175,327 |
Sector | Financials | Health |
52-Week High | $15.36 | $147.53 |
52-Week Low | $10.72 | $69.09 |
Typical Hold Time | 22 Days | 70 Days |
Enterprise Value | $15.25B | $37.76B |
Dividend Yield | 0.35% | 2.9% |
Signals from Pluang's Aura AI — not financial advice
Flagstar Bank (FLG) trades at $11.44, up 1.24% with a bearish technical outlook despite recent earnings volatility. The company reported mixed quarterly results with Q2 2026 missing EPS estimates but maintains analyst optimism with a $17.07 consensus target. Fundamentals show improving profitability with net income turning positive in 2026, while valuation metrics present a mixed picture with high P/E but attractive P/B ratio of 0.62.
The stock offers potential upside from current depressed levels given the significant discount to book value and strong analyst buy ratings (60% consensus). Key risks include ongoing earnings volatility, competitive banking pressures, and the challenge of sustaining recent profitability improvements amid economic uncertainty.
Zoetis (ZTS) trades at $74.38, up 3.96% in the last session, with a bullish technical signal and strong profitability metrics including a 71.67% gross margin and 27.69% net income margin. Recent earnings show mixed results, with a beat in Q2 2026 but a miss in Q1 2026, while Q3 2026 results are pending. The company maintains robust cash flow from operations of $2.90B in 2025 and a solid balance sheet with $1.99B in cash. Analyst consensus is a Buy with a $87.33 price target, though sentiment is tempered by near-term competitive pressures.
The outlook for ZTS is cautiously optimistic, supported by industry-leading margins and a diversified product portfolio, but faces headwinds from U.S. companion animal market weakness and increased competition. Investment opportunity lies in its undervalued P/E of 11.92 relative to growth potential, while risks include pricing erosion and volume declines. The stock's current level near resistance at $74 suggests potential for consolidation before further gains.
Trailing returns across standard periods
Latest headlines on both assets
Flagstar Bank is a prominent US financial institution and a subsidiary of New York Community Bancorp. It provides commercial banking, mortgage services, and diverse personal finance products.
Read more on FLG →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →